Equities analysts expect Viewray Inc (NASDAQ:VRAY) to report sales of $12.36 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Viewray’s earnings, with estimates ranging from $11.82 million to $12.65 million. Viewray reported sales of $700,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 1,665.7%. The company is expected to issue its next earnings report on Monday, August 6th.
On average, analysts expect that Viewray will report full-year sales of $87.46 million for the current fiscal year, with estimates ranging from $85.65 million to $89.20 million. For the next financial year, analysts forecast that the firm will report sales of $146.97 million per share, with estimates ranging from $125.48 million to $159.42 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Viewray.
Viewray (NASDAQ:VRAY) last posted its earnings results on Thursday, May 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.09. The company had revenue of $26.19 million for the quarter, compared to analysts’ expectations of $15.50 million. Viewray had a negative return on equity of 1,375.57% and a negative net margin of 83.09%. Viewray’s quarterly revenue was up 2029.3% on a year-over-year basis. During the same period last year, the firm earned ($0.54) earnings per share.
VRAY has been the topic of several recent analyst reports. Mizuho reissued a “buy” rating and issued a $12.00 target price on shares of Viewray in a research note on Thursday, April 19th. Cantor Fitzgerald reissued a “buy” rating and issued a $13.00 target price on shares of Viewray in a research note on Friday, May 11th. ValuEngine raised Viewray from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, BidaskClub raised Viewray from a “sell” rating to a “hold” rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $11.90.
Viewray opened at $7.46 on Friday, according to MarketBeat.com. The company has a current ratio of 3.79, a quick ratio of 3.04 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $542.38 million, a P/E ratio of -7.17 and a beta of 0.56. Viewray has a 1 year low of $4.40 and a 1 year high of $10.64.
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its position in Viewray by 0.4% during the 1st quarter. BlackRock Inc. now owns 1,859,946 shares of the company’s stock valued at $11,960,000 after acquiring an additional 6,678 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Viewray by 15.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 61,260 shares of the company’s stock valued at $394,000 after acquiring an additional 8,260 shares in the last quarter. PEAK6 Investments L.P. bought a new stake in Viewray during the 4th quarter valued at approximately $148,000. MetLife Investment Advisors LLC bought a new stake in Viewray during the 4th quarter valued at approximately $148,000. Finally, Wells Fargo & Company MN boosted its position in Viewray by 52.3% during the 4th quarter. Wells Fargo & Company MN now owns 57,571 shares of the company’s stock valued at $533,000 after acquiring an additional 19,769 shares in the last quarter. 83.36% of the stock is currently owned by institutional investors and hedge funds.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.